Jimenez R E, Warshaw A L, Rattner D W, Willett C G, McGrath D, Fernandez-del Castillo C
Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
Arch Surg. 2000 Apr;135(4):409-14; discussion 414-5. doi: 10.1001/archsurg.135.4.409.
Staging laparoscopy in patients with pancreatic cancer identifies unsuspected metastases, allows treatment selection, and helps predict survival.
Inception cohort.
Tertiary referral center.
A total of 125 consecutive patients with radiographic stage II to III pancreatic ductal adenocarcinoma who underwent staging laparoscopy with peritoneal cytologic examination between July 1994 and November 1998. Seventy-eight proximal tumors and 47 distal tumors were localized.
Based on the findings of spiral computed tomography (CT) and laparoscopy, patients were stratified into 3 groups. Group 1 patients had unsuspected metastases found at laparoscopy and were palliatedwithout further operation. Group 2 patients had no demonstrable metastases, but CT indicated unresectability due to vessel invasion. This group underwent external beam radiation with fluorouracil chemotherapy followed in selected cases by intraoperative radiation. Patients in group 3 had no metastases or definitive vessel invasion and were resection candidates.
Survival.
Staging laparoscopy revealed unsuspected metastases in 39 patients (31.2%), with 9 having positive cytologic test results as the only evidence of metastatic disease (group 1). Fifty-five patients (44.0%) had localized but unresectable carcinoma (group 2), of whom 2 (3.6%) did not tolerate treatment, 20 (36.4%) developed metastatic disease during treatment, and 21 (38.2%) received intraoperative radiation. Of 31 patients with potentially resectable tumors (group 3), resection for cure was performed in 23 (resectability rate, 74.2%). Median survival was 7.5 months for patients with metastatic disease, 10.5 months for those receiving chemoradiation, and 14.5 months for those who underwent tumor resection (P = .01 for group 2 vs. group 1; P<.001 for group 3 vs group 1).
Staging laparoscopy, combined with spiral CT, allowed stratification of patients into 3 treatment groups that correlated with treatment opportunity and subsequent survival. Among the 125 patients, laparoscopy obviated 39 unnecessary operations and irradiation in patients with metastatic disease not detectable by CT. Laparoscopic staging can help focus aggressive treatment on patients with pancreatic cancer who might benefit.
对胰腺癌患者进行分期腹腔镜检查可发现未被怀疑的转移灶,有助于选择治疗方案,并有助于预测生存率。
起始队列研究。
三级转诊中心。
1994年7月至1998年11月期间,共有125例经影像学检查为II至III期胰腺导管腺癌的连续患者接受了分期腹腔镜检查及腹膜细胞学检查。其中78例为近端肿瘤,47例为远端肿瘤。
根据螺旋计算机断层扫描(CT)和腹腔镜检查结果,将患者分为3组。第1组患者在腹腔镜检查中发现有未被怀疑的转移灶,仅接受姑息治疗而未进一步手术。第2组患者未发现明显转移灶,但CT显示因血管侵犯而无法切除。该组患者接受外照射及氟尿嘧啶化疗,部分患者随后接受术中放疗。第3组患者无转移灶或无明确的血管侵犯,为手术切除候选者。
生存率。
分期腹腔镜检查发现39例患者(31.2%)有未被怀疑的转移灶,其中9例细胞学检查结果阳性是转移疾病的唯一证据(第1组)。55例患者(44.0%)有局限性但无法切除的癌(第2组),其中2例(3.6%)不耐受治疗,20例(36.4%)在治疗期间发生转移疾病,21例(38.2%)接受了术中放疗。31例有潜在可切除肿瘤的患者(第3组)中,23例进行了根治性切除(切除率为74.2%)。转移疾病患者的中位生存期为7.5个月,接受放化疗的患者为10.5个月,接受肿瘤切除的患者为14.5个月(第2组与第1组比较,P = 0.01;第3组与第1组比较,P<0.001)。
分期腹腔镜检查联合螺旋CT可将患者分为3个治疗组,这与治疗机会及随后的生存率相关。在这125例患者中,腹腔镜检查避免了39例CT未检测到转移疾病患者的不必要手术和放疗。腹腔镜分期有助于将积极的治疗集中于可能受益的胰腺癌患者。